VAXON Biotech is a private company, located in Paris - France, that was founded in 2004. The company develops innovative therapeutic vaccines for the treatment of cancer (solid tumours) including lung, prostate, breast, renal, liver and colorectal cancer, using its proprietary technology of optimized cryptic peptides.

Vaxon Biotech's vaccines are intended to treat existing cancers (therapeutic vaccines) by stimulating the immune system to recognize and attack human cancer cells without harming normal cells. These vaccines target antigens, overexpressed in tumor cells while present in very low quantities in normal cells.

VAXON has a pipeline of tumor vaccines which cover major HLA-I to treat most cancer patients. The most advanced vaccine, Vx-001, has completed a "proof of principle" Phase I/II clinical trial. Vx-001 has shown good tolerance and elicited a strong immune response in most individuals, with a very significant clinical activity in patients with advanced cancers, especially Non Small Cell Lung Cancer (NSCLC), breast cancer and HepatoCellular Cancer (HCC). Vx-001 will enter in Q4-2010 a randomized, multicenter pivotal phase III study in NSCLC, aiming a marketing autorization in 2014-2015.
Vx-001 has obtained an orphan drug designation for NSCLC from EMA (European Medicines Agency) in November 2007 and from FDA (Food and Drug Administration, US) in February 2009. Vx-001 development plan and more particularly the phase III clinical trial, was approved by EMA (protocol assistance process, October 2008).